Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract: Sintered, carbon friction materials are made from fibrous materials that are impregnated with resins prior to sintering. Preferably, non-woven fibrous materials are impregnated with phenolic resin and sintered at 400 to 8000 C. The resulting material has an open porosity above 50 percent by volume.

Abstract: A wet friction material for use in a wet clutch includes a friction interfacing surface for experiencing frictional engagement with an opposed surface in the presence of a lubricant. At least a portion of the friction interfacing surface comprises fibrillated nanofibers, which define a nanofibrous web, and friction adjusting particles held by the nanofibrous web. A cured resin may adhere the fibrillated nanofibers and the friction adjusting particles to provide structural support for the friction material.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract: One exemplary embodiment includes a friction material including a base including a plurality of fibers. The base including an engagement surface, and a plurality of binder particles and friction modifying particles at the engagement surface.

Abstract: A supercapacitor having a main energy storage form that is based on the electrode reaction of electrochemical active materials in a thin liquid layer near the inner and outer surfaces of porous electrodes.

Abstract: Form controls can be reused so that the control can be bound to large volumes of data without adverse performance issues because of a large number of controls. A maximum number of rows of data N that can appear in a form are calculated. A container in memory is created for N+2 rows. The additional two rows are used to store the row after the last displayed row and the row previous to the first displayed row. In response to a user scroll or tab operation, rows within the container are reused. Child controls are hosted by the control and are also reused when the data is scrolled out of view.

Abstract: One embodiment of the invention may include a product comprising: a friction material comprising a plurality of fibers having a fiber diameter ranging from about 1 to about 20 micrometers, the fibers comprising ceramic or mineral fibers and reinforcing fibers to add strength, the reinforcing fibers being fibrillated with a Canadian Standard Freeness greater than 300.

Abstract: A friction material including a plurality of fibers and a resin component binding the fibers, and wherein the resin component includes an elastic resin.

Abstract: Sintered, carbon friction materials are made from fibrous materials that are impregnated with resins prior to sintering. Preferably, non-woven fibrous materials are impregnated with phenolic resin and sintered at 400 to 8000 C. The resulting material has an open porosity above 50 percent by volume.

Abstract: This friction material has a fibrous base material and preferably is a wet friction material for use in a fluid environment. The fibers have a small diameter and a high tensile modulus resulting in flexible fibers that performs well in a high temperature, high pressure fluid environment. The fibers have a diameter ranging from 1 to 20 micrometers and a tensile modulus greater than 70 Gpa. In the preferred embodiment, the small diameter fibers are small diameter carbon fibers or small diameter mineral fibers.

Abstract: Form controls can be reused so that the control can be bound to large volumes of data without adverse performance issues because of a large number of controls. A maximum number of rows of data N that can appear in a form are calculated. A container in memory is created for N+2 rows. The additional two rows are used to store the row after the last displayed row and the row previous to the first displayed row. In response to a user scroll or tab operation, rows within the container are reused. Child controls are hosted by the control and are also reused when the data is scrolled out of view.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract: The present invention provides a supercapacitor comprising: a) a positive electrode member comprising a solid material comprising pores and an electrically conductive current collector element bonded to said positive electrode member, wherein the pores comprise a non-flowing liquid comprising a first redox reagent; b) a negative electrode member comprising a solid material comprising pores and an electrically conductive current collector element bonded to said negative electrode member wherein the pores comprise a non-flowing liquid comprising a second redox reagent; and c) a separator member disposed between the positive electrode member and the negative electrode member, wherein the separator member comprising an ion exchange membrane, wherein the positive electrode member and the negative electrode member are bonded to opposite interface surfaces of the separator member.